Literature DB >> 11050582

Relative frequency of various forms of primary cutaneous lymphomas.

H S Zackheim1, E C Vonderheid, D L Ramsay, P E LeBoit, J Rothfleisch, M Kashani-Sabet.   

Abstract

BACKGROUND: Data on the relative frequency of the various forms of primary cutaneous lymphomas (PCLs) are largely limited to European institutions.
OBJECTIVE: Our purpose was to document the relative frequencies of various PCLs seen at 3 US institutions with active cutaneous lymphoma programs and to compare those with the European data.
METHODS: Included in this study are newly registered patients seen at MCP Hahnemann University, New York University, and the University of California, San Francisco from July 1, 1995 to June 30, 1998.
RESULTS: A total of 755 patients were seen. The frequency distribution of the major diagnostic groups was as follows: mycosis fungoides/Sézary syndrome, 82.3%; lymphomatoid papulosis, 12.6% (including patients with associated mycosis fungoides/Sézary syndrome); CD30(+) anaplastic large-cell lymphoma, 0.9%; peripheral T-cell lymphomas, 2.9%; B-cell lymphoma, 4.5%.
CONCLUSION: The most striking finding is the much lower relative frequency of primary cutaneous B-cell lymphomas at US institutions (4.5%) versus the approximately 20% reported by European groups. The reason for this difference requires further study.

Entities:  

Mesh:

Year:  2000        PMID: 11050582     DOI: 10.1067/mjd.2000.110071

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  12 in total

1.  Results of radiotherapy in primary cutaneous lymphoma.

Authors:  Carlos Conill; Begoña Navalpotro; Ingrid López; Teresa Estrach
Journal:  Clin Transl Oncol       Date:  2006-06       Impact factor: 3.405

2.  Primary cutaneous CD30+ anaplastic large cell lymphoma: report of a rare case.

Authors:  Melanie Pauline G Chao-Lo; Daisy King-Ismael; Rolando A Lopez
Journal:  J Dermatol Case Rep       Date:  2008-10-11

3.  Primary cutaneous large B-cell lymphoma, leg type: Report of two cases and review of literature.

Authors:  Santosh Kumar Mondal; Palash Kumar Mandal; Shravasti Roy; Pranab Kumar Biswas
Journal:  Indian J Med Paediatr Oncol       Date:  2012-01

Review 4.  T-small cell disorders.

Authors:  E H Westin; D L Longo
Journal:  Curr Treat Options Oncol       Date:  2001-06

5.  Primary MALT Type Skin Lymphoma-Is 'Wait and See' a Possible Strategy?

Authors:  Florentina Silvia Delli; Thomas Zaraboukas; Ioanna Mandekou-Lefaki
Journal:  Clin Med Oncol       Date:  2008-03-19

6.  Excellent Outcome of Immunomodulation or Bruton's Tyrosine Kinase Inhibition in Highly Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.

Authors:  Eva Gupta; Joseph Accurso; Jason Sluzevich; David M Menke; Han W Tun
Journal:  Rare Tumors       Date:  2015-12-29

7.  Primary Cutaneous B-cell Lymphomas: Case Report of Two Cases.

Authors:  Shashank Mishra; Divya Shelly; K V Vinu Balraam; Reena Bharadwaj
Journal:  Indian J Dermatol       Date:  2017 Nov-Dec       Impact factor: 1.494

8.  A Literature Revision in Primary Cutaneous B-cell Lymphoma.

Authors:  R La Selva; S Alberti Violetti; C Delfino; V Grandi; S Cicchelli; C Tomasini; M T Fierro; E Berti; N Pimpinelli; P Quaglino
Journal:  Indian J Dermatol       Date:  2017 Mar-Apr       Impact factor: 1.494

9.  Oral and Cutaneous Lymphomas other than Mycosis Fungoides and Sézary Syndrome in a Mexican Cohort: Recategorization and Evaluation of International Geographical Disparities.

Authors:  Amparo Hernández-Salazar; Jorge Andrés García-Vera; Yann Charli-Joseph; Guadalupe Ortiz-Pedroza; Silvia Méndez-Flores; Rocío Orozco-Topete; Ana Lilia Morales-Leyte; Judith Domínguez-Cherit; Carmen Lome-Maldonado
Journal:  Indian J Dermatol       Date:  2017 Mar-Apr       Impact factor: 1.494

10.  Efficacy and safety of bexarotene combined with photo(chemo)therapy for cutaneous T-cell lymphoma.

Authors:  Akimichi Morita; Chiharu Tateishi; Shinnosuke Muramatsu; Ryouji Kubo; Eri Yonezawa; Hiroshi Kato; Emi Nishida; Daisuke Tsuruta
Journal:  J Dermatol       Date:  2020-03-18       Impact factor: 4.005

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.